.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Express Scripts
Mallinckrodt
Citi
Johnson and Johnson
US Department of Justice
Cerilliant
Federal Trade Commission
Boehringer Ingelheim
Farmers Insurance

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Methods and apparatus for the delivery of solid drug compositions
Abstract:The invention features an implantable device for the automatic delivery of an active ingredient according to an adjustable delivery profile. The device includes a housing; a reservoir operatively connected to the housing and arranged to store a solid composition including the active ingredient; an actuator arranged within the housing to move the solid composition from the reservoir to a transit area, wherein the solid composition exits the housing at the transit area; a controller that acts on the actuator to adjust movement of the solid composition out of the housing according to the adjustable delivery profile; and a power source arranged to provide energy to the actuator and the controller. The solid composition can be an elongate, solid composition comprising a drug, and up to 90% of a carrier, wherein the composition has a cross-section of less than 0.5 mm, and wherein the drug and the carrier are selected and compounded in a proportion such that the drug is immediately released from the carrier upon contact with a liquid.
Inventor(s): Cheikh; Roland Cherif (Issy-les-Moulineaux, FR)
Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques (Paris, FR)
Filing Date:Jun 02, 1995
Application Number:08/459,514
Claims:1. An elongate, anhydrous, homogeneous, solid drug composition, said composition comprising a drug, and up to 90% of a carrier, wherein said composition comprises a maximum cross-sectional diameter of less than 0.5 mm, and wherein said drug and said carrier are selected and compounded in a proportion such that said drug is dispersed from said solid, homogeneous composition upon contact with bodily fluids and is distributed within the patient's blood stream to achieve a blood level concentration of said drug that is within 50 percent of a blood level concentration of said drug when administered in a liquid formulation, as measured over time after any initial peaks in concentration have stabilized.

2. A composition of claim 1, wherein said composition is in the form of a filament.

3. A composition of claim 1, wherein said drug is insulin.

4. A composition of claim 1, wherein said carrier is water-soluble.

5. A composition of claim 4, wherein said carrier is selected from the group consisting of cellulose, hydroxy propyl methylcellulose, carboxy methylcellulose, hydroxy ethylcellulose, hyaluronic acid, dextrose, mannose, glucose, or gelatin.

6. A composition of claim 1, wherein said composition has a surface area to drug ratio of at least 10 square millimeters per milligram of the drug.

7. A composition of claim 1, wherein said composition comprises at least 30 percent, by weight, of said drug and up to 70 percent, by weight, of said carrier.

8. A composition of claim 1, wherein said composition comprises at least 50 percent, by weight, of said drug and up to 50 percent, by weight, of said carrier.

9. A composition of claim 1, wherein said drug is a polypeptide.

10. An elongate, anhydrous, solid drug composition of claim 1, said composition consisting essentially of at least 10 percent, by weight, of said drug and up to 90 percent, by weight, of said carrier.

11. A composition of claim 10, wherein said composition consists essentially of at least 30 percent, by weight, of said drug and up to 70 percent, by weight, of said carrier.

12. A composition of claim 7, wherein said composition consists essentially of at least 50 percent, by weight, of said drug and up to 50 percent, by weight, of said carrier.

13. A composition of claim 7, wherein said drug is a polypeptide.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
McKesson
Argus Health
Federal Trade Commission
Harvard Business School
US Department of Justice
Moodys
Cerilliant
Express Scripts
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot